TCGA-CF-A3MF-01A-12R-A21D-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.58212878
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.460
- PANCREAS_BETA_CELLS+0.460
- SPERMATOGENESIS+0.310
- BILE_ACID_METABOLISM+0.070
- COAGULATION+0.030
- MYOGENESIS+0.030
- KRAS_SIGNALING_UP-0.020
- ESTROGEN_RESPONSE_LATE-0.100
- HEDGEHOG_SIGNALING-0.100
- XENOBIOTIC_METABOLISM-0.110
Top 10 suppressed
- MYC_TARGETS_V1-0.660
- PROTEIN_SECRETION-0.620
- UNFOLDED_PROTEIN_RESPONSE-0.620
- TGF_BETA_SIGNALING-0.610
- MTORC1_SIGNALING-0.600
- MITOTIC_SPINDLE-0.590
- MYC_TARGETS_V2-0.580
- PI3K_AKT_MTOR_SIGNALING-0.570
- G2M_CHECKPOINT-0.560
- OXIDATIVE_PHOSPHORYLATION-0.550
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.990 |
| 2 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.985 |
| 3 | MNG597 | — | — | 0.985 |
| 4 | msclc569389_S35.txt | — | cohortMD1 | 0.984 |
| 5 | MDT-AP-0706 | Med | Medulloblastoma | 0.983 |
| 6 | c7d31245-5d71-4a23-8a33-4f83c4718e20 | — | — | 0.982 |
| 7 | 8ad884fa-e426-4bc0-960d-08db42d341da | — | — | 0.976 |
| 8 | MNG599 | — | — | 0.976 |
| 9 | SRR12696761 | — | — | 0.976 |
| 10 | MNG598 | — | — | 0.973 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.460 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.460 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |